Lung cancer is a complex group of disorders resulting from multiple molecular aberrations. The growth of many subtypes of lung cancer is driven by complex molecular changes (driver mutations) and different abnormal molecular cell signaling pathways. With these complex molecular subtypes, assessing, treating, and understanding lung cancer necessitates rapid evolution of clinical trials, targeted therapy development, and application of personalized medicine also known as precision medicine). with advanced NSCLC.

References

1. PMI Working Group. “The Precision Medicine Initiative Cohort Program - Building a Research Foundation for 21st Century Medicine”. National Institutes of Health (2015).
2. Collins FS and Varmus H. “A new initiative on precision Medicine”. The New England Journal of Medicine9 (2015): 793-795.
3. Ashley EA. “Towards precision medicine”. Nature Reviews Genetics 17 (2016): 507.
4. Gutierrez M E., et al. “Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities”. Clinical Lung Cancer6 (2017): 651-659.
5. Schwaederle M., et al. “Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33.32 (2015): 3817-3825.
6. NCI Dictionary of Cancer Terms (2021).
7. https://www.globenewswire.com/news-release/2018/02/09/1338351/0/en/Thermo-Fisher-Ion-520-DNA-Sequencing-Chip-Comparison-and-Cost-Analysis-Report.html
8. https://www.prnewswire.com/news-releases/global-precision-medicine-market-to-reach-14170-billion-by-2026-reports-bis-research-664364683.html
9. Sholl LM., et al. “Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience”. Journal of Thoracic Oncology 10 (2015): 768-777
10. Bhopal RS. “Racism in health and health care in Europe: reality or mirage?” European Journal of Public Health 3 (2007): 238-241.
11. Cohn EG., et al. “Distributive justice, diversity, and inclusion in precision medicine: what will success look like?” Genetic Medicine 19 (2016): 157.
12. Wendler D., et al. “Are racial and ethnic minorities less willing to participate in health research?” PLoS Medicine2 (2006): e19-19e.
13. Popejoy AB and Fullerton SM. “Genomics is failing on diversity”. Nature News7624 (2016): 161.
14. Cancer facts and figures. American Cancer Society (2019).
15. “How serious is lung cancer?” American Lung Association (2021).
16. “Lung Cancer Survival Rates”. American Cancer Society (2021).
17. Gainor JF., et al. “EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis”. Clinical Cancer Research18 (2016): 4585-4593.
18. Reck M., et al. “Pembrolizumab versus chemotherapy for PD-L1 positive non small-cell lung cancer”. The New England Journal of Medicine 19 (2016): 1823-1833.
19. Langer CJ., et al. “Carboplatin and pemetrexed with or without pembrolizumab for advanced, non- squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study”. Lancet Oncology11 (2016): 1497-1508.
20. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer, version 7. National Comprehensive Cancer Network (2019).
21. Gierman HJ., et al. “Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices”. Journal of Clinical Oncology 37 (2019): 1585-1585.

Citation

Citation: K Patel., et al. “The Role of Precision Medicine in Lung Cancer: Case Study and Review of Literature”. Acta Scientific Cancer Biology 5.11 (2021): 20-23.

Copyright

Copyright: © 2021 K Patel., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.